The Transcatheter Aortic Valve Replacement (TAVR) Market 2025 report offers an in-depth exploration of market dynamics, leveraging comprehensive secondary research to provide valuable insights. It ...

GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

It highlights the current status of market size, share, demand trends, and developmental trajectories, alongside projections for the years ahead. This analysis of the Global Transcatheter Aortic Valve ...

The TAVR market has experienced a slowdown ... and the potential for Edwards to lose modest market share to competitors. The company's strong balance sheet provides significant financial ...

However, the company has recently faced a ... $7 billion transcatheter aortic valve replacement (TAVR) market, where it holds over 50% market share. This segment generates roughly 75% of the ...

A critical component of Edwards' success is its leadership in the $7 billion transcatheter aortic valve replacement (TAVR) market, where it holds over 50% market share. This segment generates roughly ...

but the company faces increasing competition from new entrants and established players. The moderation of TAVR growth to around 6% in the first half of 2024 has raised concerns about market saturation ...

Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also ...

Polark argued that a finding related to rising mortality at six years heightened his worries over the company's core TAVR market/share. "The 6-year data point from November is not flattering and ...